DTIL vs EDIT
DTIL: Precision BioSciences is a gene editing company advancing its proprietary ARCUS platform to develop potentially curative in vivo therapies for genetic and infectious diseases. EDIT: A gene editing pioneer leveraging CRISPR technology to develop in vivo, one-time therapies for serious genetic diseases.
Side-by-side fundamentals
| Metric | DTIL | EDIT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $6.43 | $2.84 | |
| Market cap | $177M | $436M | |
| Net margin FY2025, SEC XBRL | -133.4% | -395.0% | DTIL higher |
| Operating margin FY2025, SEC XBRL | -152.2% | -394.9% | DTIL higher |
| ROE FY2025, SEC XBRL | -49.6% | -586.6% | DTIL higher |
| ROA FY2025, SEC XBRL | -29.6% | -85.8% | DTIL higher |
| Debt / equity as of 2026-09-03 | 0.49 | 0.53 | DTIL lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +20.8% | |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +27.1% | EDIT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.70 | 2.23 | |
| 1-year return as of 2026-10-08 close | +12.8% | -31.6% | DTIL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.